Pharma Stocks To Buy 2017 «1080p 2025»

The year’s biggest winners were often clinical-stage companies that secured major regulatory wins or licensing deals.

: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend. pharma stocks to buy 2017

: Soared over 440% after announcing a gene therapy partnership with Pfizer . pharma stocks to buy 2017

: Delivered a 516% return as it dominated its niche in the metabolic disease market. pharma stocks to buy 2017

: A top pick for dividends (yielding ~4.2%) and growth, with shares rising 45% in 2017 driven by Humira and its cancer drug pipeline.